FIELD: chemistry.
SUBSTANCE: described is novel compound of formula (I) 
or its pharmaceutically acceptable salt, values of radicals are given in invention formula Compound has ability to inhibit receptor mGluR5, which intends it for prevention and/or treatment of receptor mGluR5- associated disturbances. Also described is pharmaceutical composition, method of inhibiting activation of receptors mGluR5, using compound of formula (I). Described is method of obtaining compound of formula 1a or 1b structure.
EFFECT: increasing output of suitable product.
18 cl, 825 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TETRAZOLE COMPOUNDS AND USE THEREOF AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTOR | 2005 |
|
RU2372347C2 |
| HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND APPLICATION METHODS THEREOF | 2007 |
|
RU2435763C2 |
| ARYLCARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | 2003 |
|
RU2340605C2 |
| DERIVATIVES OF 2- PYRROLIDINE-2-YL-[1, 3, 4]OXADIAZOLE AND THEIR USE AS ANTIDEPRESSANT AGENTS | 2003 |
|
RU2324694C2 |
| COMPOUNDS AND COMPOSITIONS AS CANNABINOID RECEPTOR 1 INHIBITORS | 2005 |
|
RU2431635C2 |
| COMPOUNDS EXHIBITING JAK-KINASE ACTIVITY (VERSIONS), METHOD OF TREATING JAK-KINASE MEDIATED DISEASES, METHOD OF INHIBITING JAK-KINASE ACTIVITY (VERSIONS), PHARMACEUTICAL COMPOSITION OF SAID COMPOUNDS | 2006 |
|
RU2485106C2 |
| DERIVATIVES OF HYDRAZONE-PYRAOLE AND MEDICAL APPLICATION THEIROF | 2002 |
|
RU2332996C2 |
| SELECTIVE HDAC6 INHIBITORS | 2018 |
|
RU2764718C2 |
| APPLICATION OF DERIVATIVES OF PYRIDINE-2-IL-METHYLAMINE FOR RECEPTION OF MEDICAL PRODUCT INTENDED FOR TREATMENT OF SYMPTOMS OF CHRONIC PAIN OF NEUROTIC OR PSYCHOGENIC PARENTAGE | 2004 |
|
RU2359674C2 |
| MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS THROMBIN INHIBITORS | 2011 |
|
RU2639876C2 |
